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Abstract
Background: FFR is routinely used to guide percutaneous coronary interventions (PCI). Visual assessment of the
angiographic result after PCI has limited efficacy. Even when the angiographic result seems satisfactory FFR after a
PCI might be useful for identifying patients with a suboptimal interventional result and higher risk for poor clinical
outcome who might benefit from additional procedures. The aim of this meta-analysis was to investigate available
data of studies that examined clinical outcomes of patients with impaired vs. satisfactory fractional flow reserve
(FFR) after percutaneous coronary interventions (PCI).
Methods: This meta-analysis was carried out according to the Cochrane Handbook for Systematic Reviews. The
Mantel-Haenszel method using the fixed-effect meta-analysis model was used for combining the results. Studies
were identified by searching the literature through mid-January, 2016, using the following search terms: fractional
flow reserve, coronary circulation, after, percutaneous coronary intervention, balloon angioplasty, stent implantation,
and stenting. Primary endpoint was the rate of major adverse cardiac events (MACE). Secondary endpoints included
rates of death, myocardial infarction (MI), repeated revascularisation.
Results: Eight relevant studies were found including a total of 1337 patients. Of those, 492 (36.8 %) had an
impaired FFR after PCI, and 853 (63.2 %) had a satisfactory FFR after PCI. Odds ratios indicated that a low FFR
following PCI was associated with an impaired outcome: major adverse cardiac events (MACE, OR: 4.95, 95 %
confidence interval [CI]: 3.39–7.22, p <0.001); death (OR: 3.23, 95 % CI: 1.19–8.76, p = 0.022); myocardial infarction
(OR: 13.83, 95 % CI: 4.75–40.24, p <0.0001) and repeated revascularisation (OR: 4.42, 95 % CI: 2.73–7.15, p <0.0001).
Conclusions: Compared to a satisfactory FFR, a persistently low FFR following PCI is associated with a worse clinical
outcome. Prospective studies are needed to identify underlying causes, determine an optimal threshold for post-PCI
FFR, and clarify whether simple additional procedures can influence the post-PCI FFR and clinical outcome.
Keywords: Coronary artery disease, Percutaneous coronary interventions, Fractional flow reserve, Intracoronary
imaging, Outcome, Meta-analysis
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Background
Fractional flow reserve (FFR) is the established gold stand-
ard used in the cardiac catheterisation laboratory to assess
the ischemic burden associated with an atheromatous
lesion of the coronary arteries. Evidence from various
clinical scenarios has shown that an FFR-guided PCI
strategy reduces the need for stenting and improves
clinical outcomes. Therefore, FFR has been incorporated in
current revascularisation guidelines [1–3]. With improved
wire technology, it is increasingly cost effective and time-
saving to use the pressure wire for diagnosis and as the
platform for any subsequent PCI [4]. Nevertheless, post-
PCI FFR measurement has not yet become part of estab-
lished clinical practice and only a minority of operators
(22 %) consider FFR to evaluate the post-stenting result [5].
Visual assessment, by angiography and quantitative
coronary angiography (QCA), has limited efficacy with
respect to identifying patients with suboptimal PCI
results and subsequent worse clinical outcomes [6, 7].
Even with an angiographic satisfactory result after PCI
19–32 % of these patients experience an adverse cardio-
vascular event during a 2-year follow-up [8]. Post-PCI FFR
measurement might be a useful indicator for the identifi-
cation of a suboptimal PCI result and, if so, would be
beneficial to both operator and patient. Of note, a recent
small prospective interventional study provides evidence
that the post-PCI FFR helps to identify patients that might
benefit from further optimisation procedures in order to
improve clinical outcome [9].
However, the value of post-PCI FFR might be con-
founded by several factors, such as gender [10] and co-
morbidities [11]. The subsequent cut-off for a satisfactory
post-PCI FFR might differ among patient populations. As
the clinical impact of post-PCI FFR has not been deter-
mined in larger scale trials this meta-analysis was setup to
examine existing data pertaining to post-PCI FFR meas-
urement and its association with clinical outcome.
Methods
This study was carried according to current recommenda-
tions of the Cochrane Handbook for Systematic Reviews
and the Meta-analysis of Observational Studies in Epidemi-
ology recommendations (MOOSE checklist, Additional
file 1: Table S1) [12]. Two authors (MW, GF) planned
and designed this meta-analysis evaluating the associ-
ation between FFR post PCI and clinical outcomes and
created an electronic database with variables of interest.
Search strategy
Medline, BIOS, and ISI Web of Science databases
were searched through January 14, 2016. Additionally,
editorials and web-based information sources (http://
www.tctmd.com, http://www.theheart.org, http://www.
europcronline.com, http://www.cardiosource.com, and
http://www.crtonline.com) were screened. The following
search terms were used: fractional flow reserve, coronary
circulation, after, percutaneous coronary intervention, bal-
loon angioplasty, stent implantation, and stenting. Refer-
ence lists of the selected articles were checked for other
relevant citations. A more detailed search strategy for
Medline can be found in the Additional file 1: Table S2.
Study selection
Studies included in the meta-analysis were published in
full text and in English. Only studies where it was possible
to clearly categorise patients into groups with low and
high post-PCI FFR were included. Two authors (MW,
GF) independently identified appropriate articles. Dis-
agreements were discussed, and a third author (GMF)
was consulted in unclear cases. All included studies were
approved by the local ethics committees and were in com-
pliance with the Helsinki Declaration.
Data extraction and quality assessment
Relevant information from each study, retrieved using a
dedicated standardised database, included study design,
baseline clinical characteristics of the study population,
and clinical outcomes. Study quality was ascertained ac-
cording to the Cochrane Handbook [12], but without
using a quality score, due to the limitations associated
with this approach [13].
Endpoints and definitions
Primary endpoint was the rate of major adverse cardiac
events (MACE) at longest follow-up. MACE was defined
according to the individual study (Table 1). Secondary
endpoints included rates of death, myocardial infarction
(MI), repeated revascularisation (repeated PCI, target ves-
sel revascularisation [TVR], target lesion revascularisation
[TLR] and CABG) and in-stent restenosis.
Data synthesis and analysis
Odds ratio and 95 % confidence intervals (CIs) for binary
outcomes were calculated. Since we mostly deal with rare
events, Mantel-Haenszel method was used for combining
the results [14]. The method can include single-zero and
double-zeroes studies. The fixed-effect meta-analysis model
was used as no relevant between-study variance was ob-
served (see Additional file 1: Table S3). Weighted incidence
of events is presented for both groups calculated according
to random-effects meta-analysis for proportions with the
Knapp-Hartung adjustment [14, 15]. Given the limitations
for the assessment of publication bias in meta-analysis with
a small study number using Funnel plots the Egger’s test
and Begg’s rank correlation test were applied (Additional
file 1: Table S4) [16, 17].
Sensitivity analyses excluded the study by Bech et al.
[18], which used only plain old balloon angioplasty (POBA)
Wolfrum et al. BMC Cardiovascular Disorders  (2016) 16:177 Page 2 of 9
for the endpoints. Because a post-PCI FFR <0.9 has been
identified as an optimal predictor of a worse clinical out-
come [19], one analysis considered only studies with an
FFR cut-off of 0.9 between low and high FFR groups. All
meta-analyses were carried out using the package metafor
in the statistical software package R, version 3.2.3 [20, 21].
Results
Included studies
A total of eight studies with 1337 patients met our inclu-
sion criteria: four prospective studies (983 patients) and
four retrospective studies (354 patients), published between
1999 and 2015 (Fig. 1). Study and population characteris-
tics are presented in Tables 1 and 2.
Main outcomes
MACE
MACE rate was defined (Table 1) and reported by all
included studies. The overall weighted incidence for
MACE was 21.4 (95 % CI: 17.0–25.8 %) in the low FFR
group and 5.0 (95 % CI: 3.5–6.4 %) in the high FFR
group (Fig. 2a). A low FFR after PCI was associated
with significantly higher odds for MACE (OR: 4.95,
95 % CI: 3.39–7.22, p <0.001).
Fig. 1 Study selection process. FFR - fractional flow reserve, PCI - percutaneous coronary intervention
Table 1 Characteristics of included studies
First author, year
of publication
Design Indication for PCI PCI technique Cut-off
for low
FFR - group
FFR technique Definition of MACE
Adenosine Pressure wire
pullback
Bech et al., [18] Retrospective Stable angina POBA <0.9 i.v. NA MACE (death, MI, recurrent
angina, CABG, repeated PTCA)
Pijls et al., [31] Prospective,
observational
All comers “stent” (type NA) ≤ 0.9 i.v. or i.c. No MACE (death, MI, CABG, TVR)
Klauss et al., [30] Retrospective Stable angina BMS < 0.95 i.c. Not mandatory MACE (death, MI, TVR)
Nam et al., [19] Retrospective 2/3 ACS, 1/3
stable angina
DES ≤ 0.9 i.c. No MACE (death, MI, TVR)
Leesar et al., [9] Prospective,
interventional
Stable angina DES > BMS < 0.96 i.c. No MACE (death, MI, TLR)
Ito et al., [23] Retrospective 92 % stable angina,
8 % unstable angina
DES plus IVUS ≤ 0.9 i.c. No MACE (cardiac death, MI, TVR,
stent thrombosis)
Reith et al., [24] Prospective,
observational
Stable angina DES > BMS
plus OCT
≤ 0.905 i.c. No MACE (death, MI, TLR)




DES plus IVUS < 0.89 i.v. or i.c. Not mandatory TVF (death and MI attributed
to target vessel, TVR)
Abbreviations: ACS acute coronary syndrome, AUC area under curve, BMS bare metal stent, CABG coronary artery bypass graft, CI confidence interval, DES drug
eluting stent, i.c. intracoronary, i.v. intravenous, IVUS intravascular ultrasound, FFR fractional flow reserve, FU follow up, MACE major adverse cardiac events,
MI myocardial infarction, Mo months, N patient number, NA not applicable, OCT optical coherence tomography, TLR target lesion revascularisation, TVF target
vessel failure, TVR target vessel revascularisation, PCI percutaneous coronary intervention, POBA plain old balloon angioplasty
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Death
Overall rate of death was reported by seven studies
involving 1230 patients. The weighted incidence for
overall death was 1.7 % (95 % CI: 0.6–2.9 %) in the low
FFR group and 0.8 % (95 % CI: 0.0–1.7 %) in the high
FFR group (Fig. 2b). A low FFR after PCI was associated
with significantly higher risk of death (OR: 3.23, 95 % CI:
1.19–8.76, p = 0.022).
Myocardial infarction
The event rate for MI was reported by all included studies.
The weighted incidence for MI was 3.3 (95 % CI: 1.1–
5.6 %) in the low FFR group and 0.8 % (95 % CI: 0.2–1.4 %)
in the high FFR group (Fig. 2c). A low FFR after PCI
was associated with significantly higher risk of MI during
follow-up (OR: 13.83, 95 % CI: 4.75–40.24, p < 0.0001).
Repeated revascularisation
Data for repeated revascularisation was available for
repeated PCI from three studies, and for CABG from
5 studies. There was an increased risk for repeated
revascularisation for patients in the low FFR group,
compared to patients in the high FFR group (OR:
4.42, 95 % CI: 2.73–7.15, p < 0.0001, Fig. 2d): repeated
PCI (OR: 3.81, 95 % CI: 2.26–6.43, p < 0.0001), CABG
(OR: 6.35, 95 % CI: 1.96–20.54, p = 0.002,). Four stud-
ies included data about TVR [9, 19, 22, 23], and two
studies about TLR [9, 24], and these indicated that
the risk for both endpoints was higher for patients
with impaired FFR after PCI: TVR (OR: 3.40, 95 %
CI: 1.44–8.03, p = 0.005), TLR (OR: 5.48, 95 % CI:
1.12–26.78, p = 0.036). Two studies reported the rate of
in-stent restenosis [9, 19]. The weighted incidence for
in-stent restenosis was 16.9 % (95 % CI: 8.2–25.6 %) in
the low FFR group and 3.4 % (95 % CI: 0.0–7.5 %) in
the high FFR group. A low FFR after PCI was associ-
ated with significantly higher risk of in-stent restenosis
(OR: 4.93, 95 % CI: 1.32–18.37, p = 0.018).
Sensitivity analysis
After excluding the study by Bech et al. [18], the results
still demonstrated that patients with a low post-PCI FFR
Table 2 Patient characteristics
Bech et al. Pijls et al. Klauss et al. Nam et al. Leesar et al. Ito et al. Reith et al. Doh et al. Combined
FFR group Low High Low High Low High Low High Low High Low High Low High Low High Low High
N 32 26 237 507 53 66 40 40 31 35 53 44 26 40 20 95 492 853
Age (years) (SD) 61.5 62 (11) 62 (10) 62 (10) 63 (8) 63 (11) 60 (12) 71 (9) 69 (10) 69 (10) 64 (9) 65 (4) 64 (4)
64 (4)
Male (%) 69 NA 75 78 70 77 70 75 88 75 83 80 77
77
HTN (%) 33 51 79 58 43 68 94 92 65 88 82 63 74
61
Diabetes (%) 17 24 26 20 8 32 23 37 58 53 51 34 28
28
HC (%) 31 61 83 10 15 58 74 85 54 60 68 37 49
61
Smoking (%) 24 48 38 28 48 32 46 54 15 23 30 26 38
41
FHx (%) 41 38 38 NA NA NA 39 63 NA 40
Prior MI (%) 17 NA 56 10 13 NA NA NA 5.6 25
MVD (%) NA NA 67 63 60 NA NA 73 68 63 67 64
65
LAD (%) 66 52 39 83 55 39 34 56 NA 100 71 71 59
54
Complex lesiona (%) NA NA 65 90 78 NA NA NA 95 67 92 70
72
FU (months) 24 6 6 12 24 18 20 23 16
Separate data provided for low FFR group and high FFR group if available from respective study, otherwise overall value
Abbreviations: FHx family history, FFR fractional flow reserve, FU follow up, HC hypercholesterolemia, HTN Hypertension, LAD left anterior descending artery,
MI myocardial infarction, MVD multi-vessel-disease, N patient number, SD standard deviation
aComplex lesion is defined as B2 or C category according to American College of Cardiology/American Heart Association (ACC/AHA) lesion classification
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had a significantly higher risk for all main outcomes
than patients in the high FFR group (Additional file
1: Figure S1): MACE (OR: 4.93, 95 % CI: 3.33–7.29, p <
0.0001), death (OR: 3.03, 95 % CI: 1.11–8.28, p = 0.03), MI
(OR: 13.45, 95 % CI: 4.63–39.05, p < 0.0001) and repeated
PCI (OR: 3.96, 95 % CI: 2.29–6.85, p < 0.0001). When
only studies with an FFR cut-off of 0.9 were included
(Additional file 1: Figure S2), the results showed that
patients in the low FFR group had significantly higher
risk than the high FFR group for MACE (OR: 4.92,
95 % CI: 3.11–7.78, p < 0.0001), myocardial infarction
(OR: 10.02, 95 % CI: 3.33–30.12, p < 0.0001), and a stat-
istical trend towards higher risk for overall death (OR:
3.70, 95 % CI: 0.89–15.43, p = 0.073). Other endpoints
were not included in this analysis, as the number of ap-
propriate studies was ≤ 2.
Discussion
Post-PCI FFR as an indicator of clinical outcome
Results of the meta-analysis reported herein, which in-
cluded different clinical scenarios and data from different
era of interventional cardiology, support the hypothesis
that a persistently low FFR following PCI is associated
with an adverse clinical outcome. We found that patients
with an impaired post-PCI FFR had significantly increased
risk for the primary endpoint of MACE, as well as for the
secondary endpoints of death, myocardial infarction, and
repeat revascularization (PCI and CABG). These results
were not changed by the exclusion of data from one study
that used only POBA [18], a technique known to convey a
higher risk for MACE than stenting [25, 26].
Data supporting present findings of the primary endpoint
of MACE comes from a study by Johnson et al. [27], which
primarily studied the continuous relationship between
pre-PCI FFR and clinical outcomes. A small sub-analysis
of this study focused on FFR measured immediately after
stenting and showed that low FFR is inversely correlated
with subsequent adverse events in both continuous (Cox
hazard ratio: 0.86, 95 % CI: 0.80–0.93; P < 0.001) and ter-
tile (log- rank P < 0.001) analyses.
Causes of persistently low FFR after PCI
A number of factors can cause a post-PCI pressure drop
over a treated epicardial segment, eventually leading to an
Fig. 2 Forest plots of odds ratios (OR) for major adverse cardiac events (MACE, Panel a), death (Panel b), myocardial infarction (Panel c) and
repeated revascularisation (Panel d). Markers represent point estimates of odds ratios, marker size represents study weight. Horizontal bars indicate
95 % confidence intervals (CI). FFR - fractional flow reserve
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impaired FFR, including incomplete stent expansion, stent
malapposition, “geographical miss,” plaque protrusion,
edge dissection, and plaque shift at the stent edge (Fig. 3).
The pathophysiological concept is explained by the
Hagen-Poiseuille law (e.g. if malapposition or plaque pro-
trusion is present): the pressure loss is caused by viscous
friction along a treated segment. Additionally, e.g. if incom-
plete stent-expansion or geographical miss is considered
the Bernoulli’s law can be applied. In this scenario residual
narrowing leads to a conversion of pressure into kinetic
energy. As a substantial amount of energy is lost due to the
presence of turbulent flow not the entire coronary pressure
can be recovered at the exit of the target lesion. Even
without a significant narrowing a suboptimal PCI result
can cause turbulent flow within and beyond the treated
coronary segment (stent malapposition, plaque protrusion,
edge dissection, plaque shift at the stent edge), especially
during the hyperaemic phase of FFR assessment, when
high flow rates of blood are induced. The switch from
laminar to turbulent flow results in the formation of
eddies and a dramatic increase in flow resistance, leading
to a pressure drop downstream from the treated coronary
segment. The total pressure loss during hyperaemia causes
the impaired FFR.
The first study to establish a link between a persistent
pressure gradient and a suboptimal stent result was pub-
lished by Hanekamp et al., who used quantitative coronary
angiography, intravascular ultrasound, and coronary pres-
sure measurement to assess deployment of coil stents
[28]. They found a close relationship between poor PCI
results, such as stent underexpansion and/or malapposi-
tion, and suboptimal stent symmetry, and in-stent gradi-
ents. Another study using slotted-tube stents found that a
post-stent FFR <0.96 predicted a suboptimal stent result
identified by IVUS [29]. In 70 % of those patients, a low
post-stent FFR was linked to incomplete stent expansion.
Studies using drug eluting stents confirmed a substantial
rate of under-expanded stents in patients with low post-
stent FFR, despite reasonable angiographic results [22, 30].
One of these studies found that low post-stent FFR corre-
lated with adverse clinical outcomes at three years [22].
A number of additional factors can affect the final
results of stent implantation and account for the relation-
ship between post-PCI FFR and clinical outcome. Ito et al.
suggested a link between high residual plaque volume,
identified by IVUS, and impaired post-stent FFR after DES
implantation [23]. Patients with high residual plaque had a
significantly higher rate of MACE after 18 months.
Lesion complexity may also affect the final result of stent-
implantation. Two included studies of our meta-analysis
reported a significant lower FFR in patients with com-
plex lesions [19, 22]. In both studies a low FFR post
PCI was associated with a significantly higher rates of
MACE rates (Table 2). Stent dimensions were also re-
ported to influence post-stent FFR and clinical outcome
[19, 22, 31]. Stents with greater length or smaller diam-
eter were significantly correlated with a low post-stent
FFR and higher MACE rates. These observations might
Fig. 3 Potential causes of suboptimal FFR after percutaneous coronary interventions. Panel a ‘geographical miss’ (diseased reference segment).
Panel b stent mal-apposition. Panel c stent under-expansion. Panel d intrastent plaque-protrusion/thrombus. Panel e edge dissection. MLA - minimal
lumen area, REF - proximal reference segment
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help to explain the previously described association be-
tween these characteristics in BMS and DES procedures
and higher subsequent event rates [32–34].
Variations in post-PCI FFR and ultimately outcome
seem to be linked to different coronary arteries. A sub-
optimal post-stent FFR was more frequent in patients
with a PCI to the left anterior descending (LAD) artery
than to the right coronary artery or left circumflex [19, 22].
This finding presumably reflects the larger myocardial
territory subtended by the LAD, leading to greater peak
flow and lower post-stent FFR for any given residual
stenosis in this vessel. Interestingly, in the aforemen-
tioned studies an impaired post-PCI FFR was associated
with higher rate of MACE.
Potential clinical application of the results
Based on the results of our meta-analysis, use of a pres-
sure wire to check the PCI result seems to be a promising
concept, even after PCI with an apparently satisfactory
angiographic result. Measurement of post-PCI FFR is
especially appropriate when a pressure wire was used
before PCI to guide the treatment strategy. If FFR remains
low after PCI and a pressure wire pullback manoeuvre
during maximal hyperaemia demonstrates a step increase
of pressure within or close to the stent edges subsequent
intravascular imaging might provide the ability to identify
causes of suboptimal post-PCI FFR (Fig. 3). Based on the
result of imaging, simple additional procedures could im-
prove the interventional result. However, only one small
previous study has prospectively examined whether add-
itional interventions can reduce the risk of future MACE
in patients with low post-PCI FFR [9]. Their results
suggested that consistent postdilatation after coronary
stenting in patients with a post-stent FFR ≥0.96 could
achieve consequently favourable clinical outcomes in
53 % of patients.
In contrast, a continuous gradual reduction in FFR dur-
ing pressure wire pullback manoeuvre along the course of
the coronary artery suggests diffuse CAD. The observation
of diffuse CAD may not be evident from an angio-
graphic examination, but can lead to severely impaired
FFR (<0.75), with myocardial ischemia and high rates of
MACE [35]. For example, diffuse CAD is more com-
mon in patients with diabetes mellitus and, in these
patients, is often associated with impaired post-stent
FFR, despite an angiographically optimal PCI [36]. Thus,
low post-stent FFR without a notable point of decrease
could indicate advanced diffuse CAD, associated with a
relatively high MACE rate. This is an important finding
as further interventional optimisation of PCI is not a
promising option for diffuse CAD and should be deferred.
Patients with diffuse CAD might benefit from a stronger
medical secondary prevention or from prolonged dual anti-
platelet therapy. However, at current stage these strategies
are only hypothetical and need validation in large scale
randomised clinical trials.
Study limitations
Most of the studies included in the meta-analysis were
retrospective or observational and, therefore, were subject
to patient selection bias, lack of independent event adjudi-
cation, heterogeneity in event definitions, and differences
in the duration of follow-up (Tables 1 and 2). With the
exception of one large multicenter registry [31], most
of the studies had small sample sizes, ranging from 60
to 119 patients. Most studies had no restrictions with
regard to co-morbidities, which led to a generally het-
erogeneous patient population (Table 2).
The existing data on post-PCI FFR covers a wide range
of coronary interventions, including POBA, BMS, and first
and second generation DES (Table 1). Because different
stent designs differentially affect blood flow and post-stent
FFR, the results must be considered hypothesis-generating.
Furthermore, induction of hyperaemic FFR was accom-
plished by intracoronary adenosine in the majority of
trials, so the results cannot entirely be compared to
cases using intravenous adenosine, especially in com-
bination with pressure wire pullback.
Some of the studies included in the meta-analysis used
different cut-off points to distinguish between low and high
FFR groups. Therefore, we included a sensitivity analysis
that considered only studies with an FFR cut-off of 0.9, the
value identified as an optimal predictor for a worse clinical
outcome following PCI [19]. The results demonstrated a
significantly higher risk for patients in the low FFR group
for MACE and myocardial infarction, and a trend towards
a higher risk for overall death. However, prospective valid-
ation of this cut-off is an important future challenge. It is
conceivable that the optimal cut-off will vary among differ-
ent coronary arteries and different clinical scenarios, simi-
lar to results of FFR assessment before PCI [27].
Furthermore, current data provides evidence only for the
use of conventional FFR. However, alternative modes of
physiological assessment are promising such as the instant-
aneous wave-free ratio (iFR). iFR assess the severity of a
coronary stenosis using a pressure wire without the need
for potent vasodilators. This might be an advantage over
FFR as it obviates the need for adenosine, which is contra-
indicated in some patients and could safe time and costs in
the cathlab. Especially with the introduction of iFR pullback
(iFR Scout™, Volcano Corporation, San Diego, California) it
seems to be a promising concept for the assessment of the
PCI result. However, no data exists on this topic yet and
further research is strongly warranted.
Conclusion
Results of the meta-analysis presented herein provide
evidence that a persistently low FFR following PCI is
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associated with an adverse clinical outcome. Prospective
studies are warranted to determine an optimal threshold
(or thresholds, in different scenarios) for post-PCI FFR.
Observational studies using intra-coronary imaging, such
as IVUS and OCT, have suggested different underlying
causes for a suboptimal FFR. Large prospective studies
are needed to confirm that these are the responsible
mechanisms and to examine whether additional simple
procedures can influence post-stent FFR and potentially
improve clinical outcome.
Additional file
Additional file 1: This supplement contains additional methods and
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